13F Holdings
中文EN

REVB REVELATION BIOSCIENCES, INC.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1810560 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-49.6%
TTM EPS YoY122.6%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-133.4%
ROA-106.3%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets27.8%
Debt / equity0.00x
Current ratio3.98x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.83x
Accruals ratio-18.0%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue—————
R&D expense$4.06M$3.55M$4.15M$5.38M$6.91M
SG&A expense$5.01M$4.43M$4.51M$5.49M$5.04M
Operating income-$9.07M-$7.98M-$8.66M-$10.86M-$11.95M
Interest expense————$41,759
Income tax$0$0$0$0$0
Net income-$8.91M-$15.04M-$120,254-$10.83M-$11.99M
EBITDA-$9.04M-$7.95M-$8.63M-$10.84M-$11.93M
EPS (basic)-23.95-1,052.16-8.44-149.20-42.50
EPS (diluted)-23.95-1,052.16-8.44-149.20-42.50
Weighted avg. shares (diluted)620,78514,29314,24672,585282,035
Balance sheet
Cash & equivalents$10.70M$6.50M$11.99M$5.25M$1.27M
Current assets$10.81M$6.57M$12.15M$5.41M$1.91M
PP&E, net$18,067$56,332$65,084$90,133$115,181
Total assets$11.58M$6.62M$12.21M$5.50M$2.04M
Current liabilities$2.00M$1.91M$5.56M$4.45M$2.14M
Total liabilities$2.72M$1.91M$5.56M$4.45M$2.14M
Shareholders' equity$8.86M$4.71M$6.65M$1.05M-$99,470
Shares outstanding226,33043,52616,48477,375282,039
Cash flow statement
Operating cash flow-$8.27M-$18.32M-$7.29M-$11.22M-$11.09M
Capital expenditure—$19,171——$131,963
Free cash flow—-$18.34M——-$11.22M
Investing cash flow—-$19,171——-$131,963
Financing cash flow$12.47M$12.85M$14.03M$15.20M$8.00M
Depreciation & amortization$27,058$27,923$25,049$25,048$16,782
Stock-based compensation$595,368$168,850$155,721$301,116$470,878
Share buybacks————$35.50M

Free plan shows the latest 5 periods; Pro shows all 7 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.